Volume : 09, Issue : 01, January – 2022
Title:
21.PREVALENCE OF MULTIPLE SCLEROSIS (MS) DISEASE AMONG SAUDI POPULATION, KSA: A CROSS-SECTIONAL STUDY
Authors :
Dr. Manal Abdulaziz Murad , Dr. Ahmed Abdullah Alharthi , Dr. Abdulaziz Ayed Alshammari , Dr. Manar Naif Bokhari , Dr. Abdulhakeem Abdullah Attar, Dr.Talal saleh alzubaidi , Dr. Khader Mohammed Almathami , Dr. Traad Louai Zarei , Dr. Seham Salem Almohammadi ¬, Dr. Razan Saleem Alsinani , Dr. Lama Abdullah Alowaydi , Dr. Rayan Hussain alobaidi , Dr. Anmar Khalid Aljuhani , Dr. Abdulaziz Mari AlQahtani , Dr. Norah Talea A Almuwallad
Abstract :
Background: Multiple sclerosis (MS) is an inflammatory disease of the central nervous system that affects the brain and spinal cord and usually begins in early adulthood. The disease still leaves many questions unanswered and its course, symptoms and therapeutic success vary so much from patient to patient that general statements can only be made to a limited extent. For this reason, MS is also known as the “Disease with a 1000 Faces”.
Methods: This was an analytical cross-sectional study to spot light on the prevalence of MS among Saudi population. The study was carried out at universities, hospitals and malls in KSA. Data were collected from patients and general population during a period from April to October 2021.
Results: There were 704 females who were the majority of the study (70%) and the rest of participants were males (n= 301). Moreover, the most prevalent age group was 20-30 years of age (n= 441, 34.9%) and the least age group was more than 50 (n= 57, 5.7%). Also, majority of participants were non-smokers (n= 853, 84.9%). Furthermore, there were 71 participants had family history of multiple sclerosis (7.1%), and there were 23 participants have multiple sclerosis. With regards to MS risk factors, 477 participants had vit D deficiency, 39 had IBD, 34 had psoriasis, 19 had pernicious anemia, 12 had infectious mononucleosis and 7 had EBV.
Cite This Article:
Please cite this article in press Manal abdulaziz Murad et al, Prevalence Of Multiple Sclerosis (MS) Disease Among Saudi Population, KSA: A Cross-Sectional Study ., Indo Am. J. P. Sci, 2022; 09(01).
Number of Downloads : 10
References:
1. Huang W-J, Chen W-W, Zhang X. Multiple sclerosis: Pathology, diagnosis and treatments. Exp Ther Med. 2017 Jun;13(6):3163–6.
2. Dutta R, Trapp BD. Relapsing and progressive forms of multiple sclerosis: insights from pathology. Curr Opin Neurol. 2014 Jun;27(3):271–8.
3. Howard J, Trevick S, Younger DS. Epidemiology of Multiple Sclerosis. Neurol Clin. 2016 Nov;34(4):919–39.
4. Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2016 Jan;172(1):3–13.
5. Ghasemi N, Razavi S, Nikzad E. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell J. 2017;19(1):1–10.
6. Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol. 2011 Sep;9(3):409–16.
7. Lane M, Yadav V. Multiple Sclerosis. Textbook of Natural Medicine. 2020. p. 1587-1599.e3.
8. Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, et al. Natural history of multiple sclerosis symptoms. Int J MS Care. 2013;15(3):146–58.
9. Hunter SF. Overview and diagnosis of multiple sclerosis. Am J Manag Care. 2016 Jun;22(6 Suppl):s141-50.
10. Traboulsee AL, Li DKB. The role of MRI in the diagnosis of multiple sclerosis. Adv Neurol. 2006;98:125–46.
11. Hartung HP, Graf J, Aktas O, Mares J, Barnett MH. Diagnosis of multiple sclerosis: Revisions of the McDonald criteria 2017 – Continuity and change. Curr Opin Neurol. 2019 Jun;32(3):327–37.
12. Confavreux C, Vukusic S. The clinical course of multiple sclerosis. Handb Clin Neurol. 2014;122:343–69.
13. Klineova S, Lublin FD. Clinical Course of Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018 Sep;8(9).
14. Nourbakhsh B, Mowry EM. Multiple Sclerosis Risk Factors and Pathogenesis. Continuum (Minneap Minn). 2019 Jun;25(3):596–610.
15. Lin R, Charlesworth J, van der Mei I, Taylor B V. The genetics of multiple sclerosis. Pract Neurol. 2012 Oct;12(5):279–88.
16. Aljumah M, Alroughani R, Alsharoqi I, Bohlega SA, Dahdaleh M, Deleu D, et al. Future of management of multiple sclerosis in the middle East: a consensus view from specialists in ten countries. Mult Scler Int. 2013;2013:952321.
17. Hudaif HSA, Bwardi NA, Kojan S. P049 – Assessment of multiple sclerosis awareness and knowledge among the Saudi population in Riyadh City. Mult Scler Relat Disord [Internet]. 2014;3(6):758. Available from: https://www.sciencedirect.com/science/article/pii/S2211034814003022
18. Amer M, AlZahrani W, AlZahrani A, Altalhi F, Alrubaie S, Alsini R, et al. ASSESSMENT OF MULTIPLE SCLEROSIS AWARENESS: KNOWLEDGE AND ATTITUDE AMONG SAUDI POPULATION IN TAIF CITY, KSA. Int J Adv Res. 2016 Dec 31;4(12):1758–66.
19. Solntseva E, Bukanova J. Assessment of knowledge and attitude of women in Majmaah city, Saudi Arabia about multiple sclerosis, 2016. J Neurol Neurophysiol [Internet]. 2016 [cited 2021 Nov 30];07(05):5. Available from: https://www.iomcworld.org/proceedings/assessment-of-knowledge-and-attitude-of-women-in-majmaah-city-saudi-arabia-about-multiple-sclerosis-2016-49021.html
20. Lolli F, Rovero P, Chelli M, Papini AM. Toward biomarkers in multiple sclerosis: new advances. Expert Rev Neurother. 2006 May;6(5):781–94.
21. Miller JR. The importance of early diagnosis of multiple sclerosis. J Manag Care Pharm. 2004 Jun;10(3 Suppl B):S4-11.
22. Yamout BI, Dahdaleh M, Al Jumah MA, Al-Shammri S, Al Sharoqi I, Al-Tahan AR, et al. Adherence to disease-modifying drugs in patients with multiple sclerosis: a consensus statement from the Middle East MS Advisory Group. Int J Neurosci. 2010 Apr;120(4):273–9.
23. Kampman MT, Steffensen LH, Mellgren SI, Jørgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler. 2012 Aug;18(8):1144–51.
24. Derakhshandi H, Etemadifar M, Feizi A, Abtahi S-H, Minagar A, Abtahi M-A, et al. Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial. Acta Neurol Belg. 2013 Sep;113(3):257–63.
25. Hedström AK, Lima Bomfim I, Barcellos L, Gianfrancesco M, Schaefer C, Kockum I, et al. Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis. Neurology. 2014 Mar;82(10):865–72.
26. Gold R, Wolinsky JS, Amato MP, Comi G. Evolving expectations around early management of multiple sclerosis. Ther Adv Neurol Disord. 2010 Nov;3(6):351–67.
27. Arhan E, Serdaroglu A, Soysal S, Ozcelik A, Gucuyener K, Demir E. Assessment of mothers’ knowledge and perceptions of electroencephalography and determination of the short-term effect of an informational leaflet. Epilepsy Behav. 2009 Aug;15(4):491–5.